Corporate Governance
This page is intended for investors and commercial partners.
Mereo’s Board of Directors sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of our Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of our business.
To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the Company’s best interests or as required by applicable laws and regulations.
Board Committees
| MEMBER | NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | AUDIT AND RISK COMMITTEE |
REMUNERATION COMMITTEE | RESEARCH AND DEVELOPMENT COMMITTEE |
|---|---|---|---|---|
| Michael Wyzga | C | M | ||
| Dr. Jeremy Bender | M | M | ||
| Dr. Anders Ekblom | C | C | ||
| Dr. Pierre Jacquet | M | M | ||
| Dr. Annalisa Jenkins | M | |||
| Dr. Deepa Pakianathan | C | M | ||
| Justin Roberts | M | M | ||
| Dr. Daniel Shames | M | |||
| Marc Yoskowitz | M |
C Chairperson M Member
Board diversity matrix (as of 21 December 2023)
| Country of Principal Executive Offices | United Kingdom |
| Foreign Private Issuer | Yes |
| Total Number Directors | 10 |
Part I: Gender Identity
| Female | Male | Non-Binary | Did Not Disclose Gender Identity | |
|---|---|---|---|---|
| Directors | 3 | 3 | 0 | 4 |
Part II: Demographic Background
| Female | Male | Non-Binary | Did Not Disclose Gender Identity | |
|---|---|---|---|---|
| African American or Black | 0 | 0 | 0 | 0 |
| Alaskan Native or American Indian | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 |
| Hispanic or Latinx | 0 | 0 | 0 | 0 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| White | 2 | 3 | 0 | 0 |
| Two or More Races or Ethnicities | 0 | 0 | 0 | 0 |
| LGBTQ+ | 0 | |||
| Did Not Disclose Demographic Background | 4 | |||
Corporate social responsibility
The Board recognizes the importance of social, environmental and ethical matters and it endeavors to consider the differing interests of the Company's stakeholders, including its investors, employees, suppliers and business partners, when operating its business
Transparency - Support for patients' organizations & their activities
Patients' organizations play a key role in supporting work to improve diagnosis, treatment and care for many therapeutic areas where pharmaceutical companies may be active. This is particularly important in the field of rare diseases, where expertise is rare and where patients may often be the experts in their own or their family’s disease or condition.
In most cases, patient representative organizations rely on support from external sources, including from pharmaceutical and biotech companies.
Mereo respects the legitimate role played by patient organizations in improving health outcomes for people with rare diseases and is actively engaged in supporting efforts by this expert community.
As part of our commitment to create sustainable value to patients, shareholders and to the community, Mereo also supports transparency initiatives, including transparency in our interactions with and support for patient organizations and their activities.
In order to secure future collaboration and to increase public awareness, we are committed to making our support – both financial and in-kind – to patients’ organizations, and to their related scientific meetings, publicly available on an annual basis.
- Transparency Disclosure - Support to Healthcare Professionals and Patients' Groups 2024
- Transparency Disclosure - Support to Healthcare Professionals and Patients' Groups 2023
- Transparency Disclosure - Support to Healthcare Professionals and Patients' Groups 2022
- Transparency Disclosure - Support to Healthcare Professionals 2021
- Transparency Disclosure - Support for Patients' Groups 2021
- The IMPACT Survey (Living with Osteogenesis IMPerfecta: understAnding experiences based on Community InsighT & evidence)
- Transparency Disclosure 2020
- Support for Patients' Groups 2019
- Support for Healthcare Professionals 2019
- Support for Patients' Groups and Scientific Meetings 2018
The IMPACT Survey (Living with Osteogenesis Imperfecta: Understanding Experiences Based on Community Insight & Evidence)
Mereo is financially supporting the development and delivery of the IMPACT Survey, a joint initiative with the Osteogenesis Imperfecta Foundation (OIF) and the Osteogenesis Imperfecta Federation Europe (OIFE) to capture and quantify the impact of OI on people’s lives and on national healthcare systems. The survey is made financially possible by a full sponsorship from Mereo to the third-party scientific agency conducting the work. The content of the project is overseen by a Steering Committee comprising representatives from both OIF and OIFE, specialised physicians treating adults and children living with OI, as well as representatives from Mereo. The Steering Committee is responsible for development of the survey, analysis and reporting of the primary results. A Data Management Committee, on which Mereo has no representation, is responsible for management of the data long-term and for securing that any requests for use of the anonymised data are in the best interests of the OI community.
